Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 15:9:883727.
doi: 10.3389/fmed.2022.883727. eCollection 2022.

The Role of Quantitative and Semi-quantitative [18F]FDG-PET/CT Indices for Evaluating Disease Activity and Management of Patients With Dermatomyositis and Polymyositis

Halil Yildiz  1 , Philippe D'abadie  2 , Olivier Gheysens  2
Affiliations
Review

The Role of Quantitative and Semi-quantitative [18F]FDG-PET/CT Indices for Evaluating Disease Activity and Management of Patients With Dermatomyositis and Polymyositis

Halil Yildiz et al. Front Med (Lausanne). .

Abstract

Idiopathic inflammatory myopathies (IIM) are considered systemic diseases involving different organs and some subtypes are associated with increased cancer risk. In this review, we provide a comprehensive summary of the current use and potential applications of (semi-)quantitative [18F]FDG-PET/CT indices in patients with IIM focusing on dermatomyositis and polymyositis. Visual interpretation and (semi-)quantitative [18F]FDG-PET indices have a good overall performance to detect muscle activity but objective, robust and standardized interpretation criteria are currently lacking. [18F]FDG-PET/CT is a suitable modality to screen for malignancy in patients with myositis and may be a promising tool to detect inflammatory lung activity and to early identify patients with rapidly progressive lung disease. The latter remains to be determined in large, prospective comparative trials.

Keywords: [18F]FDG-PET/CT; cancer; dermatomyositis; interstitial lung disease; polymyositis; standardized uptake value.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow diagram.
Figure 2
Figure 2
Representative [18F]FDG-PET images in a control patient and a patient with dermatomyositis. [18F]FDG-PET maximum intensity projection image of a subject with physiologic [18F]FDG biodistribution (A) and a representative patient with dermatomyositis (B). Proximal and symmetrical heterogeneous [18F]FDG muscle uptake is observed in patient (B).
See this image and copyright information in PMC

References

    1. Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med. (1995) 122:715–24. 10.7326/0003-4819-122-9-199505010-00010 - DOI - PubMed
    1. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. (2015) 372:1734–47. 10.1056/NEJMra1402225 - DOI - PubMed
    1. Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol. (2018) 75:1528–37. 10.1001/jamaneurol.2018.2598 - DOI - PMC - PubMed
    1. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. (1975) 292:403–7. 10.1056/NEJM197502202920807 - DOI - PubMed
    1. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. (2003) 362:971–82. 10.1016/S0140-6736(03)14368-1 - DOI - PubMed

LinkOut - more resources